← Back to Search

Contingency Management for Substance Use Disorders

N/A

Waitlist Available

Led By Robert Levy, MD

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have an active prescription for buprenorphine-naloxone (Suboxone)

At least 18 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days post-intervention

Awards & highlights

Study Summary

This trial will test a contingency management program for patients with opioid use disorder starting outpatient addiction medicine services. The goal is to improve patient outcomes and treatment retention.

Who is the study for?

This trial is for adults over 18 with Opioid Use Disorder and/or Stimulant Use Disorder who recently started opioid addiction treatment at Broadway Family Medicine. They must be prescribed buprenorphine-naloxone (Suboxone). Those with dementia, developmental disabilities, or low cognitive function, or those on amphetamines can't join the abstinence-based part but may join the attendance-only part.Check my eligibility

What is being tested?

The study tests Contingency Management (CM) in a primary care setting. CM rewards patients financially for attending addiction medicine appointments and staying substance-free. The goal is to see if this approach helps people stick with their outpatient treatment programs better.See study design

What are the potential side effects?

Since this trial involves behavioral intervention rather than medication, traditional side effects are not applicable. However, participants might experience stress or anxiety related to meeting the requirements of the program to receive incentives.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently prescribed Suboxone.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days post-intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days post-intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of CM for OUD in primary care: Recruitment

Feasibility of CM for OUD in primary care: Retention

Preliminary efficacy of CM on clinical outcomes: Urine toxicology

+1 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Attendance-only CMExperimental Treatment1 Intervention

Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments.

Group II: Attendance + abstinence CMExperimental Treatment1 Intervention

Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program.

Group III: Treatment as usual (TAU)Active Control1 Intervention

These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Contingency Management

2003

Completed Phase 2

~3220

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor

1,377 Previous Clinical Trials

1,588,254 Total Patients Enrolled

Robert Levy, MDPrincipal InvestigatorUniversity of Minnesota

4 Previous Clinical Trials

143 Total Patients Enrolled

Media Library

Contingency Management Clinical Trial Eligibility Overview. Trial Name: NCT05288751 — N/A

Opioid Use Disorder Research Study Groups: Treatment as usual (TAU), Attendance-only CM, Attendance + abstinence CM

Opioid Use Disorder Clinical Trial 2023: Contingency Management Highlights & Side Effects. Trial Name: NCT05288751 — N/A

Contingency Management 2023 Treatment Timeline for Medical Study. Trial Name: NCT05288751 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any volunteers being welcomed into the research project at this time?

"Affirmative. Clinicaltrials.gov records demonstrate that this trial, which initially went public on June 15th 2022, is actively recruiting participants; 200 individuals will be enrolled at one medical site in total."

Answered by AI

What is the current participation rate for this clinical experiment?

"Affirmative, clinicaltrials.gov exhibits that this trial is actively recruiting patients since its inception on June 15th 2022 and the most recent update also indicates that 200 individuals will be recruited from one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

2022. "Contingency Management for Opioid and Stimulant Use Disorders in Primary Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05288751.

All > Probuphine